Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

Despite having no symptoms, Linda’s commitment to preventive care led to a life-saving lung cancer diagnosis. Learn why early ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a prostate, testicular, and penile cancers ...

The primary end point is rPFS by PSMA PET-CT as assessed by blinded independent central review (BICR). Secondary end points include metastasis-free survival by conventional imaging by BIRC, time to ...

PET/CT scans were acquired according to local protocol (applying EANM (European Association of Nuclear Medicine) PET procedure guidelines for FDG studies), 9 but the following conditions were ...

Minimal residual disease-negativity after treatment in DLBCL strongly correlates with remission and overall survival. However ...

Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Michael Hofman presented an in-depth ...

GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for ...

The pivotal AMPLIFY trial aims to support FDA approval of ⁶⁴Cu-SAR-bisPSMA as a best-in-class imaging tool in prostate cancer ...

Breast cancer remains a leading cause of cancer-related mortality globally, underscoring the critical need for early ...